Eschenbach D A, Nugent R P, Rao A V, Cotch M F, Gibbs R S, Lipscomb K A, Martin D H, Pastorek J G, Rettig P J, Carey J C
University of Washington, Seattle.
Am J Obstet Gynecol. 1991 Mar;164(3):734-42. doi: 10.1016/0002-9378(91)90506-m.
Ureaplasma urealyticum has been associated with low birth weight and histologic chorioamnionitis and it is a frequent isolate from the chorioamnion of patients who are delivered prematurely. In prior clinical trials using antibiotics active against U. urealyticum, antibiotic treatment was associated with reduced prematurity and increased mean birth weight. In this multicenter, randomized, double-blind clinical trial, pregnant women with U. urealyticum were treated with 333 mg of erythromycin base or placebo three times daily, starting between 26 and 30 weeks' gestation and continuing through 35 completed weeks of pregnancy. Women with urinary tract infection or Neisseria gonorrhoeae infection were excluded from the trial, and women with Chlamydia trachomatis or group B streptococci were excluded from these analyses. Erythromycin did not eliminate U. urealyticum from the lower genital tract. There were no significant differences between erythromycin- and placebo-treated women in infant birth weight or gestational age at delivery, in frequency of premature rupture of membranes, or in neonatal outcome.
解脲脲原体与低出生体重和组织学绒毛膜羊膜炎有关，并且它是早产患者绒毛膜中常见的分离菌。在先前使用对解脲脲原体有活性的抗生素的临床试验中，抗生素治疗与早产减少和平均出生体重增加有关。在这项多中心、随机、双盲临床试验中，患有解脲脲原体的孕妇从妊娠26至30周开始，每天三次服用333毫克红霉素碱或安慰剂，持续至妊娠35周结束。患有尿路感染或淋病奈瑟菌感染的女性被排除在试验之外，沙眼衣原体或B族链球菌感染的女性被排除在这些分析之外。红霉素未能清除下生殖道中的解脲脲原体。在婴儿出生体重、分娩时的孕周、胎膜早破频率或新生儿结局方面，接受红霉素治疗和安慰剂治疗的女性之间没有显著差异。
